

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,

on June 17, 2002.

By: Jeffrey Gillis



Atty. Docket No. DX0903K1

PATENT

RECEIVED

JUN 27 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

J. Fernando BAZAN

Serial No.: 09/963,347

Filed: September 25, 2001

For: MAMMALIAN CYTOKINES;
RELATED REAGENTS AND
METHODS

Examiner: not yet assigned

Art Unit: 1646

INFORMATION DISCLOSURE
STATEMENT

Palo Alto, California 94304

June 18, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

Sir:

The materials as listed in the attached modified PTO 1449 form are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98.

Attached please find the PTO 1449 form listing references AB-AK, all of which were cited in the parent application, USSN 09/399,492, and should therefore be available there. As such, copies of these references will not be provided absent specific request.

Applicants would like to draw attention to reference AA. In the parent application, USSN 09/399,492, in an Office Action dated 3/26/01, the Examiner cited

GenBank database. The enclosed US Patent, which was cited in the attached 1449 form, was listed in the GenBank printout and has therefore been included in the US Patent. Should this not be correct Applicants request the opportunity to

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that an exhaustive search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached modified PTO 1449 form. Applicants further request that all such art be listed on the front of any patent issuing from this application.

Since this Information Disclosure Statement is being filed before receiving the first Office action, applicants believe no fee is required for filing this document; however, if such a fee is required the Commissioner is hereby authorized to charge DNAX Research Institute's Deposit Account No. 04-1239.

Respectfully submitted,


June 18, 2002

By: Sheela Mohan-Peterson
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

Enclosures:

1. Modified PTO 1449 forms listing references AA-AK (11 references, 1 page).
2. Reference AA (1 ref)
3. Return postcard.

COPY ~~MADE~~
ORIGINALLY FILED



RECEIVED

JUN 27 2002

Sheet 1 of 1

TECH CENTER 1600/2900

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
FOR PATENT

(Use several sheets if necessary)

ATTY. DOCKET NO.: DX0903K1	SERIAL NO.: 09/963,347
APPLICANT: J. Fernando Bazan	
FILING DATE: Sept. 25, 2001	GROUP: 1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	5,965,122	10/12/99	A. Namen, et al.			June 9, 1997

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
AB	0314415A2	5/3/89	EPO				
AC	WO 00/29581	5/25/00	PCT			X	
AD	WO 00/39149	7/6/00	PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Sherree Lee Friend, <i>et al.</i> , <i>Experimental Hematology</i> , 22(3):321-328, 1994. "A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells"
AF	Steven D. Levin, <i>et al.</i> , <i>Journal of Immunology</i> , 162(2):677-683, January, 1999. "Thymic Stromal Lymphoprotein: A cytokine that promotes the development of IgM+ B cells in Vitro and Signals via a novel mechanism"
AG	G.G. Mahairas, <i>et al.</i> , GenBank, Accession Number AQ781833, August 2, 1999. Definition: "HS_3148_A2_C03_T7C CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3148 Col=6 Row=E, genomic survey sequence"
AH	Markus J. Maeurer, <i>et al.</i> , <i>The Cytokine Handbook</i> , 3rd ed., Ch. 9:229-269. Thomson, ed. (Academic Press, Inc., San Diego, California) 1998. "Interleukin-7"
AI	M. Marra, <i>et al.</i> , GenBank, Accession Number AA717930, December 29, 1997. Definition: "vt09f05.r1 Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone IMAGE: 1162593 5', mRNA sequence"
AJ	M. Marra, <i>et al.</i> , GenBank, Accession Number AI591430, April 21, 1999. Definition: "vt09f05.r1 Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone IMAGE: 1162593 5', mRNA sequence"
AK	NCI-CGAP, GenBank, Accession Number AA889581, January 4, 1999. Definition: "ak25a11.sl Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 14072603', mRNA sequence"

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.